Merck has scrapped a £1 billion expansion plan in the United Kingdom, blaming the decision on insufficient state backing. The cancellation removes one of the larger foreign-investment commitments the British government had been pursuing in its life-sciences sector this year, and lands as ministers press harder for inward capital.

What did Merck announce?

The German science and technology company confirmed it will not proceed with the £1bn UK project. Merck had been in advanced discussions with Whitehall over fiscal support, and the failure to land a satisfactory package triggered the withdrawal. No alternative UK site or scaled-down replacement has been disclosed by either side.

Why is the project being cancelled?

Company executives cited a lack of state investment as the deciding factor. Merck had pressed ministers for additional commitments to make the project commercially viable against competing jurisdictions in Europe and the United States. The reversal exposes the limits of Britain's current industrial-policy toolkit when bidding for capital-intensive research and manufacturing projects.

What are the stakes for British industrial policy?

The withdrawal hands Whitehall a high-profile setback at a moment when ministers have been actively courting global life-sciences capital. Pharmaceuticals and biotechnology sit at the centre of the government's growth strategy, and inward investment ranks as a key measure of sector health. The Merck reversal shows how quickly overseas groups can redirect capital when UK fiscal incentives fall short.

The episode sharpens pressure on several policy fronts:

• The reputational cost to the UK's inward-investment pipeline
• Calls on HM Treasury to revisit grant and tax-credit frameworks
• The competitive position of Britain against EU and US jurisdictions
• The viability of the government's broader sector-deal ambitions

What is Merck's UK footprint?

Merck KGaA, headquartered in Darmstadt, Germany, operates across healthcare, life science, and electronics. The group runs a long-established UK presence and has historically used Britain as a hub for research, manufacturing, and distribution. The decision to walk away from the £1bn project marks a setback for the company's British operations and comes amid wider consolidation across European pharmaceuticals.

What happens next?

The UK government has yet to comment publicly on the breakdown. Merck has not confirmed whether alternative UK sites or scaled-down investments remain under consideration. Industry observers expect the decision to feed into a wider debate over how Britain finances large-scale research infrastructure, particularly as private capital flows into UK science parks have softened in recent quarters.

The withdrawal lands at a sensitive moment for Whitehall. HM Treasury is weighing options for the next budget cycle, and the Department for Business and Trade is preparing an updated life-sciences sector plan. Whether the government can rebuild credibility with foreign investors after this reversal will shape the next round of inward-investment decisions across UK advanced manufacturing.